Chromosome 5 is one of the largest human chromosomes, spanning about 178 million base pairs, yet it carries a surprisingly low density of protein-coding genes compared to its size. Despite housing only around 923 known protein-coding genes, these genes punch well above their weight: they include clusters that wire neurons in the developing brain, orchestrate immune responses, and guard against uncontrolled cell growth. When parts of chromosome 5 are deleted, duplicated, or mutated, the consequences range from rare childhood syndromes to common inflammatory diseases and several forms of cancer.
Size, Structure, and a Paradox
The complete sequence of chromosome 5, published in 2004, revealed something unexpected. While the chromosome is physically large, much of its DNA does not code for proteins. Instead, large stretches are occupied by noncoding sequences that are remarkably similar across vertebrates, from humans down to fish. That kind of evolutionary conservation across hundreds of millions of years strongly suggests these regions do something important, even though researchers are still working out exactly what. The chromosome also contains many internal duplications, regions where chunks of DNA have been copied and pasted at different locations along its length, which can predispose it to structural rearrangements during cell division.1PubMed. The DNA sequence and comparative analysis of human chromosome 5
What chromosome 5 lacks in sheer gene count, it makes up for in functional variety. Its genes fall into several distinct clusters, each responsible for a different biological system. Two of the most studied are the protocadherin cluster, which is central to brain development, and the cytokine gene cluster on the long arm (5q), which plays a major role in immune regulation. Mutations in individual genes scattered across chromosome 5 also cause well-known conditions like spinal muscular atrophy, Treacher Collins syndrome, and familial adenomatous polyposis.
The Protocadherin Cluster and Brain Wiring
One of chromosome 5’s most remarkable features is its cluster of protocadherin genes. These genes encode cell-surface proteins that act as molecular identity tags on neurons. Each neuron switches on a different combination of protocadherins, creating a unique barcode that allows it to distinguish itself from its neighbors. This self-recognition system prevents a neuron’s own branches from tangling with each other while still allowing it to form proper connections with other cells.2PubMed Central. Clustered protocadherins
The process matters enormously during brain development. Protocadherins guide neuron migration, help dendrites spread out evenly, prevent axons from bundling incorrectly, and influence how synapses form.3Frontiers in Neuroscience. Clustered Protocadherins Emerge as Novel Susceptibility Loci for Mental Disorders Because the system relies on combinatorial diversity, where each neuron expresses a slightly different set of these proteins, the protocadherin cluster generates an enormous number of possible identity codes from a relatively compact stretch of DNA.4PubMed Central. Wiring the Brain by Clustered Protocadherin Neural Codes
When protocadherin genes are disrupted, the consequences can be severe. Research increasingly links mutations in this cluster to susceptibility for several mental disorders, though the precise relationships are still being mapped. The idea is straightforward: if neurons cannot tell themselves apart from their neighbors, the resulting circuits get miswired, and miswired circuits can manifest as psychiatric or neurodevelopmental conditions.3Frontiers in Neuroscience. Clustered Protocadherins Emerge as Novel Susceptibility Loci for Mental Disorders
The Cytokine Gene Cluster and Immune Regulation
The long arm of chromosome 5, particularly the region labeled 5q31, is densely packed with genes that regulate the immune system. Among the most prominent are the genes for interleukin-4 (IL-4) and interleukin-13 (IL-13), two signaling molecules that sit just 12.5 kilobases apart and are often switched on together in T cells. Their close physical arrangement is not a coincidence: the two genes share regulatory elements and are activated in a coordinated fashion, especially in T cells that have been previously primed by an immune encounter.5Blood. Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31
Nearby on the same stretch of DNA sit the genes for IL-3, IL-5, and GM-CSF, three cytokines that are critical for eosinophil development. Eosinophils are white blood cells involved in fighting parasites and driving allergic inflammation. Mutations or overactivity in this region can lead to familial eosinophilia, a heritable condition in which eosinophil counts are persistently elevated.6The American Journal of Human Genetics. Familial Eosinophilia Maps to the Cytokine Gene Cluster on Human Chromosomal Region 5q31-q33
This dense immune-gene neighborhood makes the 5q31 region a hotspot for research into common inflammatory conditions, particularly asthma and Crohn’s disease.
Asthma, Allergies, and Crohn’s Disease
Because so many immune-signaling genes sit on chromosome 5q, genetic variation in this region has been linked to susceptibility for asthma and atopic (allergy-prone) conditions. Studies across multiple populations have found that variants in the IL-4 gene are associated with asthma, while variants in the IL-13 gene are strongly associated with elevated IgE levels and sensitivity to mold allergens.7PubMed Central. Variation in conserved non-coding sequences on chromosome 5q and susceptibility to asthma and atopy Earlier work on both chromosome 5q and chromosome 11 identified the IL-4 gene cluster as a candidate region for genes relevant to bronchial hyperresponsiveness.8PubMed. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness
Crohn’s disease, a chronic inflammatory condition of the gut, has a different but overlapping genetic story on chromosome 5. A roughly 250-kilobase stretch on 5q31, sometimes called the IBD5 locus, carries a risk haplotype that has been consistently associated with Crohn’s disease across multiple populations.9PubMed. Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease Pinning down which specific gene in the region drives the risk has been tricky. One candidate is a variant in SLC22A4, a transporter gene, though its effect seems to depend on the broader haplotype context rather than acting alone. Other associated variants sit in immune-regulatory genes like IRF1 and RAD50 that lie just outside the core risk haplotype.10PubMed. Sequence variation, linkage disequilibrium and association with Crohn’s disease on chromosome 5q31
Cri du Chat Syndrome
The best-known structural abnormality on chromosome 5 is a deletion on its short arm (5p), which causes Cri du Chat syndrome. The name, French for “cry of the cat,” comes from the distinctive high-pitched cry that affected infants produce, a result of abnormal laryngeal development. Beyond the characteristic cry, the condition involves intellectual disability, delayed development, a small head, and distinctive facial features.11PubMed Central. Cri du Chat syndrome
The deletion varies in size from patient to patient. Larger deletions that exceed about 10 million base pairs can be detected on a standard karyotype, while smaller ones require more sensitive testing methods.12PubMed Central. Cri-du-Chat Syndrome: Revealing a Familial Atypical Deletion in 5p A recent rat model engineered with CRISPR to carry a deletion in the corresponding chromosomal region has helped illuminate the condition’s biology, revealing inflammatory and immune disruptions alongside the expected neurological deficits.13PubMed Central. Behavioral Abnormalities, Cognitive Impairments, Synaptic Deficits, and Gene Replacement Therapy in a CRISPR Engineered Rat Model of 5p15.2 Deletion Associated With Cri du Chat Syndrome Effective treatments remain limited, and current management focuses on supportive therapies, though early intervention programs for speech and motor development can substantially improve quality of life.
Sotos Syndrome and Treacher Collins Syndrome
On the opposite end of chromosome 5, at 5q35, sits the NSD1 gene. Mutations or deletions in NSD1 cause Sotos syndrome, a condition characterized by overgrowth, distinctive facial features, and learning difficulties. In a review of 239 individuals with confirmed NSD1 mutations, facial features and learning disability were present in about 90% of cases. However, roughly one in ten had height and head size within the normal range, meaning overgrowth is a common feature but not an absolute requirement for the diagnosis.14The American Journal of Human Genetics. Genotype-Phenotype Associations in Sotos Syndrome: An Analysis of 266 Individuals with NSD1 Aberrations Some cases are caused by point mutations in the gene, while others result from large deletions that remove the NSD1 region entirely.15PubMed Central. Hyperinsulinemia in Sotos Syndrome with a de novo NSD1 Deletion
Treacher Collins syndrome is another craniofacial condition tied to chromosome 5. It results from mutations in the TCOF1 gene, which produces a protein called treacle that is essential for ribosome production in rapidly dividing cells during early embryonic development. When treacle is insufficient, the neural crest cells that give rise to facial bones and cartilage undergo excessive programmed cell death, leading to underdeveloped cheekbones, a small jaw, and malformed ears.16PubMed Central. Treacher Collins syndrome: unmasking the role of Tcof1/treacle Research has confirmed that treacle interacts directly with the machinery responsible for ribosomal RNA production, and that insufficient ribosomal RNA triggers a stress response that kills developing cells at a critical window in embryogenesis.17PubMed Central. The Treacher Collins syndrome (TCOF1) gene product is involved in ribosomal DNA gene transcription by interacting with upstream binding factor
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the most consequential single-gene diseases mapped to chromosome 5. It results from loss of function of the SMN1 gene at 5q13, usually through homozygous deletion of a critical segment called exon 7. Without a working SMN1 gene, motor neurons in the spinal cord degenerate, leading to progressive muscle weakness and, in severe forms, respiratory failure.18PubMed Central. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
The genetics of SMA are unusually nuanced because of a nearly identical backup gene called SMN2 that sits nearby on the same chromosome. SMN2 produces mostly a shortened, unstable form of the protein, but it does make a small amount of functional protein. The number of SMN2 copies a patient carries is the single strongest predictor of disease severity: more copies mean more functional protein and milder symptoms. In a minority of patients, instead of a straightforward deletion, a gene-conversion event occurs in which part of SMN1 gets replaced by the corresponding part of SMN2, effectively silencing the gene without physically removing it.19PubMed Central. Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5
SMA has become a showcase for precision gene therapy. The drug nusinersen is an antisense oligonucleotide that coaxes the SMN2 gene into including exon 7 in more of its protein products, effectively boosting the amount of functional protein. A more direct approach, onasemnogene abeparvovec (marketed as Zolgensma), uses a viral vector to deliver a complete working copy of the SMN1 gene into motor neurons.20PubMed Central. The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy The availability of newborn screening for SMA in many countries now means treatment can begin before symptoms appear, which dramatically improves outcomes.
Tay-Sachs Disease
The HEXA gene on chromosome 5 encodes a subunit of an enzyme that breaks down a fatty substance called GM2 ganglioside inside cells. When HEXA is mutated, the enzyme cannot function properly, and GM2 ganglioside accumulates in nerve cells, destroying them progressively. This is Tay-Sachs disease, a condition most commonly known in its infantile form, which typically leads to severe neurological decline within the first few years of life. Researchers have cataloged a wide variety of HEXA mutations, including deletions, splice-site changes, and missense mutations at multiple positions along the gene.21PubMed Central. Sequence of DNA flanking the exons of the HEXA gene, and identification of mutations in Tay-Sachs disease
At the molecular level, many Tay-Sachs mutations cause the defective enzyme subunit to be flagged for destruction before it ever reaches its intended destination within the cell. The cell’s quality-control machinery recognizes that the protein has folded incorrectly and routes it to the proteasome for degradation, a process that effectively eliminates whatever residual enzyme activity the mutant protein might have had.22PubMed Central. Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation Carrier screening programs, particularly within populations where certain HEXA mutations are more common, have dramatically reduced the incidence of Tay-Sachs in recent decades.
Cancer Connections on Chromosome 5
Several cancer-related genes reside on chromosome 5, and deletions of portions of the chromosome are recurrent events in certain malignancies. One of the best characterized is the APC gene at 5q21-22. Inherited mutations in APC cause familial adenomatous polyposis (FAP), a condition in which hundreds to thousands of polyps develop in the colon, virtually guaranteeing colorectal cancer if left untreated.23PubMed Central. Familial adenomatous polyposis The gene was originally mapped to chromosome 5 after researchers noticed a patient with a visible deletion in the 5q region who had both developmental abnormalities and FAP.24Nature. Localisation of the gene for familial adenomatous polyposis on chromosome 5
In blood cancers, deletion of part of the long arm of chromosome 5 defines a specific subtype of myelodysplastic syndrome (MDS) known as the 5q- syndrome. The hallmark is a severe anemia with characteristically large red blood cells. Research identified the gene RPS14, which encodes a ribosomal protein, as the key driver. Losing one copy of RPS14 disrupts the processing of ribosomal RNA in red blood cell precursors, triggering a stress response that kills them off before they mature.25Nature. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen The connection between ribosomal protein deficiency and anemia mirrors what is seen in Diamond-Blackfan anemia, a congenital bone marrow failure syndrome, linking these two conditions at a molecular level.26PubMed Central. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
Another gene on chromosome 5, MSH3, is involved in DNA mismatch repair. A common variant in MSH3 (rs26279) has been associated with a modestly increased risk of cancer overall, with the strongest associations seen for colorectal and breast cancer across multiple populations.27PubMed Central. MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis The same gene also influences how cancer cells respond to certain chemotherapy drugs, making it potentially relevant for treatment decisions.28PubMed Central. MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells
At the tip of the short arm, chromosome 5p15.33 harbors the TERT gene, which encodes the catalytic component of telomerase, the enzyme that maintains the protective caps on the ends of chromosomes. Genome-wide association studies across both European and Asian populations have consistently identified variants in TERT and the neighboring CLPTM1L gene as risk factors for lung cancer.29Carcinogenesis. Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk Fine-mapping studies in Han Chinese populations have confirmed specific TERT variants with increased lung cancer odds.30PubMed. Fine mapping of chromosome 5p15.33 identifies novel lung cancer susceptibility loci in Han Chinese
Targeted Treatments Emerging from Chromosome 5 Biology
The detailed understanding of which genes are lost in 5q deletions has enabled remarkably targeted therapies. The clearest success story is lenalidomide for the 5q- syndrome form of MDS. The drug works by promoting the degradation of a protein called CK1α, which is encoded by a gene within the commonly deleted region. Because patients with del(5q) already have only one working copy of the CK1α gene, their cells produce less of the protein to begin with and are therefore more sensitive to lenalidomide-induced degradation than normal cells. This selective vulnerability is what creates the therapeutic window: cancer cells with the deletion are hit harder than healthy cells.31Nature. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS Lenalidomide also pushes del(5q) cells toward differentiation into megakaryocytes, which then undergo cell death, further reducing the malignant population.32Nature Cell Biology. Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Resistance to lenalidomide does develop in some patients, and outcomes differ depending on the broader genetic context. Acute myeloid leukemia with an isolated 5q deletion tends to carry IDH1 or IDH2 mutations and has longer overall survival than cases where the 5q deletion is part of a complex karyotype with multiple chromosomal abnormalities.33PubMed. Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q)
TERT and the Telomere Frontier
The TERT gene’s dual role in both cancer susceptibility and aging has made it a fascinating target for experimental gene therapy. Telomerase is the enzyme that lengthens telomeres, the protective end-caps on chromosomes that shorten each time a cell divides. In cancer, telomerase is often overactive, allowing tumor cells to divide indefinitely. But in aging, telomere shortening contributes to tissue decline, and researchers have explored whether carefully controlled telomerase activation might slow that process.
In mouse studies, delivering the TERT gene via a viral vector to one- and two-year-old mice improved insulin sensitivity, bone density, and neuromuscular coordination. Median lifespan increased by 24% in the younger group and 13% in the older group. Critically, the treated mice did not develop more tumors than untreated controls, suggesting that the cancer-promoting effects of telomerase are blunted when the gene is introduced into adult or aged organisms rather than during the rapid growth phases of early life.34PubMed Central. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer Whether these results translate to humans remains to be seen. The challenge is inherently paradoxical: any therapy that boosts telomerase to combat aging must somehow avoid giving cancer cells the same longevity advantage.35PubMed Central. Telomere Gene Therapy: Polarizing Therapeutic Goals for Treatment of Various Diseases For now, this work remains firmly in the realm of animal research, but chromosome 5’s TERT gene sits squarely at the center of it.